Impact of Treatment with Renin–Angiotensin System Inhibitors on Clinical Outcomes in Hypertensive Patients Hospitalized with COVID-19

20Citations
Citations of this article
87Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Introduction: Concerns have been raised about the possible harmfulness of angiotensin-converter enzyme inhibitors (ACEi) and aldosterone receptor blockers (ARB) in patients with COVID-19. However, few data from a European population have been published, especially from hypertensive patients. Aim: To study the association between ACEi or ARB treatments and major adverse outcomes during hospitalisation in COVID-19 patients. Methods: We studied 545 consecutive hypertensive patientsadmitted to our institution due to COVID-19 with respiratory involvement. Weanalysed the incidence of combined event (death or mechanical ventilatorysupport) during hospitalisation, as well as the time to independent events. Results: 188 (34.5%) patients presentedthe combined endpoint. 182 (33.4%) patients died, and 21 (3.9%) neededmechanical ventilatory support. Patients with previous treatment with ACEi orARB presented similar incidence of the combined endpoint during hospitalisation(31.6% vs. 41.8%; p = 0.08), with a lower all-cause mortality rate (30.4% vs. 41.2%;p = 0.03) compared with those without prior treatment. Use of ACEi or ARB was not independentlyassociated with lower incidence of the combined endpoint [Adjusted OR 0.675 (95% CI 0.298–1.528; p = 0.146)], but it was associated with lower mortality [Adjusted OR 0.550 (95% CI 0.304–0.930; p = 0.047)]. Conclusions: The use of ACEi or ARB was associated with lessincidence of all-cause death during hospitalisation among hypertensive patientsadmitted with COVID-19 respiratory infection.

Cite

CITATION STYLE

APA

Negreira-Caamaño, M., Piqueras-Flores, J., Martínez-DelRio, J., Nieto-Sandoval-Martin-DeLaSierra, P., Aguila-Gordo, D., Mateo-Gomez, C., … Negreira-Caamaño, M. (2020). Impact of Treatment with Renin–Angiotensin System Inhibitors on Clinical Outcomes in Hypertensive Patients Hospitalized with COVID-19. High Blood Pressure and Cardiovascular Prevention, 27(6), 561–568. https://doi.org/10.1007/s40292-020-00409-7

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free